These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27522176)

  • 1. Trends in childhood vaccine purchase costs in the US public sector: 1996-2014.
    Chen W; Messonnier M; Zhou F
    Vaccine; 2016 Sep; 34(39):4706-4711. PubMed ID: 27522176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Childhood vaccine purchase costs in the public sector: past trends, future expectations.
    Davis MM; Zimmerman JL; Wheeler JR; Freed GL
    Am J Public Health; 2002 Dec; 92(12):1982-7. PubMed ID: 12453820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with the pricing of childhood vaccines in the U.S. public sector.
    Chen W; Messonnier M; Zhou F
    Health Econ; 2018 Feb; 27(2):252-265. PubMed ID: 28660666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in provider vaccine purchase prices and payer reimbursement.
    Freed GL; Cowan AE; Gregory S; Clark SJ
    Pediatrics; 2009 Dec; 124 Suppl 5():S459-65. PubMed ID: 19948577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Private-sector vaccine purchase costs and insurer payments: a disincentive for using combination vaccines?
    Clark SJ; Cowan AE; Freed GL
    Hum Vaccin; 2011 Apr; 7(4):426-8. PubMed ID: 21389778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspective of vaccine manufacturers on financing pediatric and adolescent vaccines in the United States.
    Shen AK; Rodewald LE; Birkhead GS
    Pediatrics; 2009 Dec; 124 Suppl 5():S540-7. PubMed ID: 19948586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variation in provider vaccine purchase prices and payer reimbursement.
    Freed GL; Cowan AE; Gregory S; Clark SJ
    Pediatrics; 2008 Dec; 122(6):1325-31. PubMed ID: 19047253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Size of clinical trials and Introductory prices of prophylactic vaccine series.
    Weinberg SH; Butchart AT; Davis MM
    Hum Vaccin Immunother; 2012 Aug; 8(8):1066-70. PubMed ID: 22854668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine.
    Isakbaeva ET; Musabaev E; Antil L; Rheingans R; Juraev R; Glass RI; Bresee JS
    Vaccine; 2007 Jan; 25(2):373-80. PubMed ID: 16930784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pricing strategies for combination pediatric vaccines based on the lowest overall cost formulary.
    Behzad B; Jacobson SH; Sewell EC
    Expert Rev Vaccines; 2012 Oct; 11(10):1189-97. PubMed ID: 23176652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gaps in vaccine financing for underinsured children in the United States.
    Lee GM; Santoli JM; Hannan C; Messonnier ML; Sabin JE; Rusinak D; Gay C; Lett SM; Lieu TA
    JAMA; 2007 Aug; 298(6):638-43. PubMed ID: 17684186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
    Brenzel L
    Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Net financial gain or loss from vaccination in pediatric medical practices.
    Coleman MS; Lindley MC; Ekong J; Rodewald L
    Pediatrics; 2009 Dec; 124 Suppl 5():S472-91. PubMed ID: 19948579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of childhood rotavirus vaccination in Germany.
    Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O
    Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine-preventable haemophilus influenza type B disease burden and cost-effectiveness of infant vaccination in Indonesia.
    Gessner BD; Sedyaningsih ER; Griffiths UK; Sutanto A; Linehan M; Mercer D; Mulholland EK; Walker DG; Steinhoff M; Nadjib M
    Pediatr Infect Dis J; 2008 May; 27(5):438-43. PubMed ID: 18398383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the cost of cholera-vaccine delivery from the societal point of view: A case of introduction of cholera vaccine in Bangladesh.
    Sarker AR; Islam Z; Khan IA; Saha A; Chowdhury F; Khan AI; Cravioto A; Clemens JD; Qadri F; Khan JA
    Vaccine; 2015 Sep; 33(38):4916-21. PubMed ID: 26232545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.
    Bryan JP; Nelson M
    Arch Intern Med; 1994 Mar; 154(6):663-8. PubMed ID: 8129500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A web-based tool for designing vaccine formularies for childhood immunization in the United States.
    Jacobson SH; Sewell EC
    J Am Med Inform Assoc; 2008; 15(5):611-9. PubMed ID: 18579833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of Haemophilus influenzae type b vaccination in Moscow, Russian Federation.
    Platonov AE; Griffiths UK; Voeykova MV; Platonova OV; Shakhanina IL; Chistyakova GG; Robertson SE;
    Vaccine; 2006 Mar; 24(13):2367-76. PubMed ID: 16413949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.